Accu_Chek Insight CGM app. Photo and Copyright: RocheUnique features and innovative design

Roche Diabetes Care’s new Accu-Chek® Guide wireless blood glucose monitoring system offers smart solutions for easier testing

                                    • Accuracy surpasses the ISO 15197:2013/EN ISO 15197:201510 requirements for blood glucose monitoring systems
                                    • Easy-to-use with an intuitive user interface and improved testing experience
                                    • Connectivity to the Accu-Chek Connect diabetes management system enables online data exchange with healthcare professionals and caregivers

Munich, Germany (September 12, 2016) – On August 31, 2016, Roche Diabetes Care received clearance by the U.S. Food and Drug Administration (FDA) for the new Accu-Chek Guide blood glucose monitoring system that has been designed to address previously unmet needs of patients and their healthcare professionals. The Accu-Chek Guide system offers a combination of unique features and an innovative design which make it easy and safe to use.

Designed to address unmet needs of people with diabetes

Appropriate use of SMBG (self-monitoring of blood glucose) can enhance diabetes self-management, and an increase in SMBG frequency is associated with a significant reduction in HbA1c values in patients on insulin therapy,1 as well as improved glycemic control with a reduced incidence of acute2,3 and longterm4-6 complications. Non-adherence to routine SMBG remains a common issue7 and people with diabetes report they would test more frequently if the procedure was easier and more discreet 8,9. The new Accu-Chek Guide system has been tailored to the specific needs of people with diabetes to make it a user-friendly system. In fact, 9 out of 10 (97%) participants surveyed agreed that the Accu-Chek Guide system is extremely easy to use14. Healthcare professionals can anticipate taking less time to train their patients on this new system, allowing them more time for valuable consult discussions.

SmartPack vial and easy-edge technology help make testing easier

Successful diabetes management relies on accurate and reliable information shared between people with diabetes, caregivers and healthcare professionals. Accu-Chek Guide offers Bluetooth® low energy connectivity to the Accu-Chek Connect diabetes management system, providing automatic data logging and secure online data sharing. Results can be transmitted wirelessly from the Accu-Chek Guide meter to the Accu-Chek Connect app on the user’s mobile device, and from there to the Accu-Chek Connect Online portal, so diabetes information can be viewed virtually anywhere for timely advice, as needed. This cloud-based solution provides a clear picture of what’s working for people with diabetes and what’s not. This approach can help turn reliable data into actionable information that can support improved outcomes for people with diabetes, their caregivers and healthcare professionals. Ultimately, connected systems can encourage patient adherence and bring relief to patients when they can make more sense of the data and make better decisions.


  1. Miller KM, et al. Diabetes Care 2013; 36: 2009-14
  2. Sämann A, et al. Diabetologia 2005; 48: 1965-70
  3. Weber C, et al. Curr Med Res Opin 2009; 25: 1197-207.
  4. ADA. Diabetes Care 2016, Standards of Medical Care in Diabetes; January 2016 Volume 39, Supplement 1 :s23-s81
  5. Diabetes Control and Complications Trial Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
  6. Nathan DM, et al. N Engl J Med 2005; 353: 2643-53
  7. Hansen MV, Diabetes Res Clin Pract. 2009;85(2):183–8
  8. Bergenstal R, et al. Diabetes Educ 2000; 26: 981-9.
  9. Ong, W.M., et al. Patient Prefer Adherence, 2014. 8: p. 237-46
  10. International Organization for Standardization (ISO). ISO 15197:2013 .
  11. Brazg RL, et al. J Diabetes Sci Technol 2013;7:144-152
  12. Brazg RL, Klaff LJ, Sussmann, AM, Parkin: Accu-Chek Guide Blood Glucose Monitoring System Exceeds International Accuracy Standards, Journal of Diabetes Science and Technology  1–2, DOI: 10.1177/1932296816652902
  13. Hinnen D, et al. J Diabetes Sci Technol. 2015 Mar; 9(2): 293–301
  14. Harvey C., et al., “Monitoring System With a Spill-Resistant Vial, Easier Strip Handling, and Connectivity to a Mobile App: Improvement of Patient Convenience and Satisfaction. Journal of Diabetes Science and Technology 1-6, DOI: 10.1177/1932296816658058

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome.

Roche Diagnostics, 12.09.2016 (tB).


Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds


Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern


Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf


Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren


Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung


NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose


Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung